For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development expenses, net of government assistance | 462 | 568 | 955 | |
| General and administrative expenses | 1,987 | 1,961 | 2,135 | |
| Loss from operating activities | -2,449 | -2,529 | -3,090 | |
| Foreign exchange gain (loss) | 4 | -8 | 10 | |
| Change in fair value of derivative warrant liabilities | 40 | -1,427 | 487 | |
| Interest and other income, net | 170 | 172 | 205 | |
| Total other income (loss), net | 134 | 1,591 | -272 | |
| Loss before income tax recovery | -2,315 | -938 | -3,362 | |
| Income tax benefit | 0 | 0 | 0 | |
| Net loss | -2,315 | -938 | -3,362 | |
| Basic EPS | -0.14 | -0.06 | -0.21 | |
| Diluted EPS | -0.14 | -0.06 | -0.21 | |
| Basic Average Shares | 16,933,620 | 15,924,522 | 15,924,522 | |
| Diluted Average Shares | 16,933,620 | 15,924,522 | 15,924,522 | |
Grace Therapeutics, Inc. (GRCE)
Grace Therapeutics, Inc. (GRCE)